°Ç°­Ä®·³

CHUNGARAM CLINIC

Ä¿¹Â´ÏƼ °Ç°­Ä®·³
Á¦¸ñ 8. ¸¸¼ºÇÇ·ÎÀÇ ¿øÀΰú Ä¡·á







ÇǷζõ ÀÓ»óÀûÀ¸·Î ÀÚ¹ßÀûÀΠȰµ¿À» ½ÃÀÛÇϰųª Áö¼ÓÇÏ´Â µ¥

À־ÀÇ ¾î·Á¿òÀ¸·Î Á¤ÀÇÇÒ ¼ö ÀÖ½À´Ï´Ù1).

 

ÇǷΰ¨ÀÌ 6°³¿ù ÀÌ»ó Áö¼ÓµÇ¸é

¸¸¼ºÇÇ·Î ÁõÈıºÀ» ÀǽÉÇØº¼ ¼ö Àִµ¥,

ÇöÀç °¡Àå ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ¸¸¼ºÇÇ·ÎÁõÈıº¿¡ ´ëÇÑ Áø´Ü±âÁØÀº

CDC 1994 criteriaÀÔ´Ï´Ù.







ÃÖ¼ÒÇÑ 6°³¿ù µ¿¾È Áö¼ÓµÇ´Â ¸¸¼º ¶Ç´Â Àç¹ß¼º,

½É°¢ÇÑ ÀáÇ༺ µ¹¹ß¼º ÇǷΰ¡ ³ªÅ¸³ª¾ß Çϰí,

ÇǷθ¦ ¼³¸íÇÒ ¼ö ÀÖ´Â ´Ù¸¥ ÀÓ»óÀû ¿øÀÎÀ»

¹èÁ¦ÇÒ ¼ö ÀÖ¾î¾ß Çϸç, ´ÙÀ½¿¡ Á¦½ÃµÈ 8°³ÀÇ Áõ»óµé Áß ÃÖ¼ÒÇÑ

4°³ ÀÌ»óÀÌ È®ÀεǾî¾ß ÇÕ´Ï´Ù.

Á¦½ÃµÈ Áõ»óµéÀº Áö¼Ó¼º ¶Ç´Â

Àç¹ß¼ºÀ¸·Î ÇÇ·Î ¹ßº´ÀϺ¸´Ù ¸ÕÀú ³ªÅ¸³ª¾ß ÇÕ´Ï´Ù.







Ư¹ß¼º¸¸¼ºÇÇ·Î(ICF)´Â 6°³¿ù ÀÌ»ó Áö¼ÓµÇ´Â

¸¸¼º Àç¹ß¼º ÇǷΰ¡ ³ªÅ¸³ª¸é¼­,

À§ÀÇ 8°¡Áö ÁÖ¿ä Áõ»óµé Áß 3°¡Áö ÀÌÇϸ¦

ÃæÁ·ÇÏ´Â °æ¿ì¿¡ Áø´ÜµÉ ¼ö ÀÖ½À´Ï´Ù2).

 

¸¸¼ºÇÇ·ÎÁõÈıºÀÇ Á¤È®ÇÑ ¿øÀÎÀº ¹àÇôÁöÁö ¾Ê¾ÒÁö¸¸

»ý¸®ÇÐÀû, ½É¸®Àû ¿äÀÎÀÌ ÇÔ²² ÀÛ¿ëÇÏ¿© ¸¸¼ºÇÇ·ÎÁõÈıºÀ» ¹ß»ý,

À¯Áö½ÃŰ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

°¡Á··Â, Á¤½Å Áúȯ(¿ì¿ïÁõ µî)µµ ¿¬°ü ÀÖ½À´Ï´Ù3).







±× ¿Ü¿¡ ÀúÇÏµÈ ¸é¿ªÃ¼°è, ³»ºÐºñ ±â´ÉÀå¾Ö, ÀÚÀ²½Å°æ½ÇÁ¶,

´Ù¾çÇÑ ¹ÙÀÌ·¯½º °¨¿°, ½ºÆ®·¹½º µî¿¡

´ëÇѽûóÇϺÎ-³úÇϼöü-

ºÎ½ÅÃà(hypothalamic-pituitary-adrenal, HPA) axisÀÇ


±â´ÉÀúÇÏ µîÀÌ Á÷°£Á¢ÀûÀ¸·Î °ü¿©ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù4).







¸¸¼º ÇǷΰ¡ ÀÖ´Ù¸é °¡º­¿î À¯»ê¼Ò ¿îµ¿ÀÌ µµ¿òÀÌ µË´Ï´Ù.

¿îµ¿ ÈÄ ÇÇ·ÎÇÏÁö ¾ÊÀ» Á¤µµ·Î¸¸

´Ü°èÀûÀ¸·Î Á¶±Ý¾¿ ¿îµ¿·®À» ´Ã¸³´Ï´Ù.

¼ö¸é°ú ½Ä½À°üµµ Áß¿äÇÕ´Ï´Ù.

¾ÆÄ§¿¡ ÇÞºµÀ» ÂØ°í, Àú³á¿¡´Â ±³°¨½Å°æ Ç×ÁøÀ»

¿¹¹æÇϱâ À§ÇØ À̿Ͽä¹ý µîÀ» Ȱ¿ëÇØ º¼ ¼ö ÀÖ½À´Ï´Ù.

»ýü½Ã°è¿Í ÀÎü¸®µë¿¡ ¸ÂÃá ½Ä»ç´Â Àå³» ¹Ì»ý¹°ÃÑÀÇ

°Ç°­ÇÑ ¿òÁ÷ÀÓ°ú ÀÏÁֱ⠸®µëÀ»

¿øÈ°ÇÏ°Ô ÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ Áß¿äÇÕ´Ï´Ù5).

 

ÇÑÀÇÇÐÀûÀ¸·Î ÇǷδ ½ÅüÀÇ Çã¾à°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù.

ȯÀÚ°¡ È£¼ÒÇÏ´Â Áõ»ó°ú Çã¾àÇÑ ºÎÀ§¿¡ µû¶ó

ºñÆó±âÇã(Þ¡øËѨúÈ), °£½ÅÀ½Çã(ÊÜãìëäúÈ),

½ÉºñÇ÷Çã(ãýÞ¡úìúÈ), ºñ½Å¾çÇã(Þ¡ãìåÕúÈ)6)

µîÀ¸·Î ºÐ·ùÇÕ´Ï´Ù. Áõ»ó°ú üÁú¿¡ µû¶ó º¸ÁßÀͱâÅÁ7),

½ÊÀü´ëº¸ÅÁ, °øÁø´Ü8) µîÀ»


±âº»À¸·Î ¾àÀ縦 Ãß°¡ÇÏ¿© ó¹æÇÕ´Ï´Ù.







¸¸¼ºÇǷηΠÇÑÀÇ¿ø¿¡ ³»¿øÇÏ½Ã¸é ±× Áõ»ó°ú ¿øÀο¡ µû¶ó

Áø¸Æ ÈÄ ÇѾà, ħ, ¶ä µîÀÇ Ä¡·á¸¦ ¹Þ°Ô µË´Ï´Ù.

ÇÊ¿ä½Ã ¿Â¿­ Ä¡·á³ª Ãß³ª Ä¡·á°¡ Ãß°¡µË´Ï´Ù.

 

¸¸¼ºÇǷο¡ ÇѾàÀ» ºñ·ÔÇÑ ¶ä°ú ħ°ú °°Àº

Ä¡·á¹ýÀÇ È¿´ÉÀÌ Àӻ󿬱¸¸¦ ÅëÇØ¼­ °ËÁõµÇ°í ÀÖ½À´Ï´Ù9)10)11).

´Ü¼ø ÇѾà Ä¡·á »Ó¸¸ ¾Æ´Ï¶ó Ãß³ª Ä¡·á´Â

À¯È¿À²¿¡¼­ ¼ö¸éÀå¾Ö¿Í ÇÇ·Î ÁßÁõµµ °³¼±ÀÌ È¿°úÀûÀÔ´Ï´Ù.

ÇѹæÄ¡·á¿¡ Ãß³ª Ä¡·á¸¦ °âÇÏ´Â °ÍÀº ÇѹæÄ¡·á¸¸ óġÇßÀ» ¶§º¸´Ù

À¯È¿À²ÀÌ ³ô¾ÒÀ¸¸ç, À¯È¿À²¿¡ ´ëÇÑ ºÐ¼®°á°úÀÇ È®½Ç¼ºµµ

ºñ±³Àû ³ô°Ô12) ³ªÅ¸³µÀ¸´Ï ¸¸¼ºÀûÀÎ ÇǷΰ¡ ÀÖ´Ù¸é


Àû±ØÀûÀ¸·Î Ä¡·á¸¦ °í·ÁÇØº¸½Ã±â¸¦ Ãßõ µå¸³´Ï´Ù.







Àü ¼¼°èÀûÀ¸·Î ¸¸¼ºÇÇ·ÎÀÇ À¯º´À²Àº ¾à 10%¿¡ ÇØ´çµÇ°í,

1%ÀÇ Àα¸´Â ¸¸¼ºÇÇ·ÎÁõÈıºÀ» ¾Î°í ÀÖÀ» °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù13).

¸¸¼ºÀûÀ¸·Î °³¼±µÇÁö ¾Ê´Â ÇǷδÂ

ȯÀÚÀÇ »îÀÇ ÁúÀ» ÀúÇϽÃ۴µ¥, ¾Ï, ³úÁ¹Áß, ±Ë¾ç, ´Ù¹ß¼º °æÈ­Áõ

µî°ú °°Àº Áúȯº¸´Ùµµ ´õ ½É°¢ÇϰÔ

»îÀÇ ÁúÀ» ¶³¾î¶ß¸®´Â °ÍÀ¸·Î º¸°íµÇ¾ú½À´Ï´Ù14).

¶ÇÇÑ ¸¸¼ºÇÇ·ÎÁõÈıº ȯÀÚÀÇ 58.6%´Â, Á÷¾÷À» °¡ÁöÁö ¸øÇÏ¿©

»çȸÀû °æÁ¦ÀûÀ¸·Îµµ Å« ¹®Á¦¸¦

¾ß±âÇÏ´Â °ÍÀ¸·Î º¸°íµÈ ¹Ù ÀÖ½À´Ï´Ù15).

 

¸¸¼ºÇÇ·Î ¿ª½Ã Áúº´ÀÌ´Ï ¹æÄ¡ÇÏÁö ¸¶½Ã°í

ÀûÀýÇÑ Ä¡·á¸¦ ¹ÞÀ¸½Ã±â¸¦ ¹Ù¶ø´Ï´Ù.​ 

 

​                                                                                          



1) Chaudhuri A&Behan PO. (2004). Fatigue in neurological disorders. Lancet, 363, 978-988. https://doi.org/10.1016/S0140-6736(04)15794-2



​2) Fukuda K, Straus SE, Hickie L, Sharpe MC, Dobbins JG, Komaroff AL. International chronic fatigue syndrome study group. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994; 121:953-9.



​3) Á¤½ÂÇÊ, and À̱ٹÌ. "¸¸¼º ÇÇ·ÎÁõÈıº." ¿µ³²ÀÇ´ëÇмúÁö 24.1 (2007): 1-10.

 ​

4) Papadopoulos AS, Cleare AJ. Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome. Nat Rev Endocrinol. 2011;8(1):22-32.​

 

5) ¹Úº´Áø. "¸¸¼ºÇǷο¡ ÀÖ¾î ¼ö¸éÀÇ ±â´ÉÀÇÇÐÀû °ü¸®." (2021): 23-28.​

 

6) Son CG. Analysis of patients visiting an oriental hospital with idiopathic chronic fatigue or chronic fatigue syndrome. J Korean Med. 2013;34:119-25.​

 

7) Nam, Donghyun, and Donghyun Nam. "The effectiveness of Bojungikgi-tang and its modifications on chronic fatigue syndrome: a systematic review and meta-analysis." Journal of Korean Medicine 41.1 (2020): 93-106.​

 

8) Kim, Ji Won, et al. ¡°Survey on Pattern Identification and Treatment of Chronic Fatigue in Korea Medicine.¡± Journal of Physiology & Pathology in Korean Medicine, vol. 32, no. 2, Korean Society of Oriental Pathology, 30 Apr. 2018, pp. 126–133. Crossref, doi:10.15188/kjopp.2018.04.32.2.126.​

 

9) Adams D, Wu T, Yang XS, Yang X, Tai S, Vohra S. Traditional Chinese medicinal herbs for the treatment of idiopathic chronic fatigue and chronic fatigue syndrome. Cochrane Database Syst Rev. 2009;(4): CD006348.​

 

10) Wang T, Zhang Q, Xue X, Yeung A. A systematic review of acupuncture and moxibustion treatment for chronic fatigue syndrome in China. Am J Chin Med. 2008;36(1):1-24​

 

11) Kim HG, Yoo SR, Park HJ, Son CG. Indirect moxibustion (CV4 and CV8) ameliorates chronic fatigue: a randomized, double-blind, controlled study. J Altern Complement Med. 2013;19(2): 134-40.​

 

12) ¼ÛÁ¤À±, ±èÁØ¿­, and ³²µ¿Çö. "¸¸¼ºÇÇ·ÎÁõÈıºÀÇ Áõ»ó°ü¸®¸¦ À§ÇÑ Ãß³ª¿ä¹ýÀÇ À¯¿ë¼º: ü°èÀûÀÎ ¹®Çå°íÂû°ú ¸ÞŸºÐ¼®." ´ëÇÑÇÑÀÇÇÐȸÁö 41.3 (2020): 205-220.​

 

13) Son CG. Review of the Prevalence of Chronic Fatigue Worldwide. J Korean Oriental Med. 212;22(2):25-33.​

 

14) Hvidberg MF, Brinth LS, Olesen Av, Petersen KD, Ehlers L. The health-related quality of life for patients with myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). PLoS ONE. 2015;10(7):e013242-e.​

 

15) Castro-Marrero J, Faro M, Zaragozá MC, Aliste L, de Sevilla TF, Alegre J. Unemployment and work disability in individuals with chronic fatigue syndrome/myalgic encephalomyelitis: a community-based cross-sectional study from Spain. BMC Public Health. 2019;19(1):840-.​

 

 

​                                                                   

 

¨Ï2022.û¾Æ¶÷Çѹ溴¿ø All rights reserved.